Summer Sale

Up to 30% off — ends 2 Aug

ONLY00h00m00s

Publisher
source

Simon Haas

2 months ago

PhD Project: Targeting Transient Adaptations of Leukemic Stem Cells to Overcome Chemotherapy Resistance in Acute Myeloid Leukemia Heidelberg University in Germany

Degree Level

PhD

Field of study

Molecular Biology

Funding

Full funding available

Deadline

Aug 31, 2026

Country flag

Country

Germany

University

Heidelberg University

Social connections

How do I apply for this?

Sign in for free to reveal details, requirements, and source links.

Apply for this position

Keywords

Molecular Biology
Cancer Biology
Biology
Medical Science
Exosome Biology
Leukemia
Xenotransplantation
Extracellular Vesicle
Bioinformatic
Transcriptomic

Suggested positions

About this position

This funded PhD project at Heidelberg University focuses on overcoming chemotherapy resistance in acute myeloid leukemia (AML) by targeting transient adaptations of leukemic stem cells. AML is a highly aggressive blood cancer characterized by the accumulation of immature myeloid cells, leading to poor clinical outcomes and high relapse rates. While chemotherapy induces remission in most cases, relapse remains a significant challenge, often due to mechanisms beyond newly acquired mutations, such as metabolic and epigenetic adaptations.

The research will leverage a comprehensive collection of bone marrow and peripheral blood samples from a large patient cohort, spanning multiple treatment stages including induction chemotherapy, remission, relapse, and refractory disease. Using advanced single cell multiomic approaches and metabolic spectral flow cytometry, the project aims to identify transcriptomic and metabolic vulnerabilities in leukemic stem cells under standard therapy. Additionally, the role of extracellular vesicles, such as exosomes, in disease persistence and relapse will be investigated.

Functional validation of findings will be performed using pre-clinical models, including bone marrow organoids and xenotransplantation platforms. The project is embedded within the SFB1709 consortium, providing access to lectures, activities, and expertise in molecular stem cell, cancer, and translational research. Close collaboration partners include Prof. Dr. Simon Haas (Charite, Berlin), Dr. Lars Velten (CRG, Barcelona), Prof. Andreas Trumpp (DKFZ, HI-STEM, Heidelberg), and Prof. Carsten Müller-Tidow (Heidelberg University Hospital).

Applicants should have a Master’s degree or equivalent in biological sciences, with skills in molecular cell biology, single-cell technologies, and bioinformatics. Good English proficiency is required. The position offers full funding and is based at Heidelberg University Hospital, Department of Hematology, Oncology and Rheumatology, in Heidelberg, Germany. The application deadline is 31 August 2026, and the project is set to start on 1 October 2026.

To apply, submit your application through the HBIGS online portal. For further information, visit the project and consortium websites or contact the HBIGS office. This opportunity is ideal for motivated candidates seeking to contribute to cutting-edge cancer research in a collaborative and interdisciplinary environment.

Funding details

Full funding including tuition fees and living expenses is available for this position. The scholarship covers all educational costs and provides a monthly stipend.

How to apply

Please submit your application including a cover letter, CV, academic transcripts, and contact information for two references. Applications should be sent via the online portal before the deadline.

More information can be found here

Ask ApplyKite AI

Start chatting
Can you summarize this position?
What qualifications are required for this position?
How should I prepare my application?

Professors